Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Phathom Pharmaceuticals Inc
PHATCurrent price
4.11 USD
+0.06 USD (+1.48%)
Last closed
4.02 USD
Company
www.phathompharma.com
ISIN
US71722W1071
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
286 951 008 USD
Yield for 12 month
-56.04 %
1Y
3Y
5Y
10Y
15Y
PHAT
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for gastrointestinal diseases. The company develops its products based on vonozopran, an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. Its products under development include VOQUEZNA, which has completed its Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and its Phase II clinical trials for the as-needed dosing for active heartburn episodes; and VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, which have completed the Phase III clinical trials for the eradication of Helicobacter pylori infection. The company has the rights in the United States, Europe, and Canada for P-CAB. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Address: 100 Campus Drive, Florham Park, NJ, United States, 07932
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
20.88 USDP/E ratio
–Dividend Yield
–Current Year
+55 252 000 USD
Last Year
+682 000 USD
Current Quarter
+29 664 000 USD
Last Quarter
+16 352 000 USD
Current Year
+47 279 000 USD
Last Year
+515 000 USD
Current Quarter
+25 849 000 USD
Last Quarter
+13 996 000 USD
Key Figures PHAT
1 year
3 years
5 years
10 years
EBITDA
-276 672 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-43.78 %
PEG Ratio
–
Return On Equity TTM
-3 489.00 %
Wall Street Target Price
20.88 USD
Revenue TTM
55 252 000 USD
Book Value
-3.70 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
4 249.60 %
Dividend Yield
–
Gross Profit TTM
47 279 000 USD
Earnings per share
-5.29 USD
Diluted Eps TTM
-5.29 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics PHAT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History PHAT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
–
Payout Ratio TTM
–
Last Split Date
–
Stock Valuation PHAT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
3.47
Price Sales TTM
5.19
Enterprise Value EBITDA
-2.20
Price Book MRQ
25.37
Financials PHAT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators PHAT
For 52 weeks
3.81 USD
19.71 USD
50 Day MA
5.26 USD
Shares Short Prior Month
14 355 935
200 Day MA
10.38 USD
Short Ratio
9.48
Shares Short
12 910 348
Short Percent
25.97 %
BeatStart